Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2022-002838-13
    Sponsor's Protocol Code Number:CLOU064A2305
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2022-11-22
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2022-002838-13
    A.3Full title of the trial
    A multicenter, open-label Phase 3 study: ambulatory blood pressure monitoring in adult patients with chronic spontaneous urticaria inadequately controlled by H1-antihistamines treated with remibrutinib up to 12 weeks
    Estudio de fase III, multicéntrico y abierto: monitorización ambulatoria de la presión arterial en pacientes adultos con urticaria crónica espontánea inadecuadamente controlada con antihistamínicos H1 y tratados con remibrutinib hasta 12 semanas
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to investigate if remibrutinib has an effect on blood pressure in patients with chronic spontaneous urticaria (CSU)
    Estudio para investigar si remibrutinib tiene efecto deseado sobre la presión arterial en pacientes con urticaria crónica espontánea (UCE).
    A.4.1Sponsor's protocol code numberCLOU064A2305
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorNovartis Farmacéutica, S.A.
    B.1.3.4CountrySpain
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportNovartis Pharma AG
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationNovartis Farmacéutica, S.A.
    B.5.2Functional name of contact pointTrial Monitoring Organization (TMo)
    B.5.3 Address:
    B.5.3.1Street AddressGran Via de les Corts Catalanes, 764
    B.5.3.2Town/ cityBarcelona
    B.5.3.3Post code08013
    B.5.3.4CountrySpain
    B.5.4Telephone number34 90 0353036
    B.5.5Fax number34 93 2479903
    B.5.6E-maileecc.novartis@novartis.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameRemibrutinib
    D.3.2Product code LOU064
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRemibrutinib
    D.3.9.2Current sponsor codeLOU064
    D.3.9.4EV Substance CodeSUB204118
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Chronic Spontaneous Urticaria
    Urticaria crónica espontánea
    E.1.1.1Medical condition in easily understood language
    Chronic Hives
    Habones Crónicos
    E.1.1.2Therapeutic area Diseases [C] - Skin and Connective Tissue Diseases [C17]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10072757
    E.1.2Term Chronic spontaneous urticaria
    E.1.2System Organ Class 10040785 - Skin and subcutaneous tissue disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To rule out an increase of >3mmHg in 24-hour average SBP at steady state (Week 4) compared to baseline, measured by ambulatory blood pressure monitoring (ABPM).
    Descartar un aumento >3 mmHg en la media de la PAS en 24 horas, en estado de equilibrio (semana 4) y respecto al valor basal, medida mediante MAPA.
    E.2.2Secondary objectives of the trial
    - To evaluate changes in 24-hour average SBP at steady state (Week 4) compared to baseline
    - To evaluate changes in 24-hour average DBP at steady state (Week 4) compared to baseline
    - To evaluate changes in daytime and nighttime average SBP at 4 weeks
    - To evaluate changes in daytime and nighttime average DBP at 4 weeks
    - To evaluate the safety and tolerability of remibrutinib
    - Evaluar los cambios en la media de la PAS en 24 horas, en estado de equilibrio (semana 4) y respecto al valor basal.
    - Evaluar los cambios en la media de la PAD en 24 horas, en estado de equilibrio (semana 4) y respecto al valor basal
    - Evaluar los cambios en la media de la PAS diurna y nocturna durante la semana 4.
    - Evaluar los cambios en la media de la PAD diurna y nocturna en la semana 4.
    - Evaluar la seguridad y tolerabilidad de remibrutinib
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    DNA sampling / Pharmacogenetics:
    The study includes an optional genetic research component.
    The purpose of genetic research may be to better understand the safety and efficacy of remibrutinib, or to learn more about human diseases, or to help develop ways to detect, monitor and treat diseases.
    As technology changes over time, the most appropriate technology will be used at the time the exploratory genetic research is performed. This may include the study of the entire genome.
    The use of DNA to search for biomarkers of disease and drug action is exploratory.
    Recogida de muestras para ADN/farmacogenética. El estudio incluye una parte de investigación genética opcional.
    El propósito de la investigación genética podría ser comprender mejor la seguridad y eficacia de remibrutinib, u obtener más información acerca de las enfermedades humanas, o ayudar a desarrollar maneras de detectar, monitorizar y tratar enfermedades.
    Dado que la tecnología cambia con el tiempo, se utilizará la tecnología más apropiada en el momento en que se lleven a cabo estudios exploratorios de investigación genética. Esto podría incluir el estudio del genoma completo.
    El ADN se utiliza para buscar biomarcadores de la enfermedad y de la acción del fármaco con fines exploratorios.
    E.3Principal inclusion criteria
    - Signed informed consent must be obtained prior to participation in the study.
    - Male and female adult participants ≥18 years of age at the time of screening.
    - CSU duration for ≥ 6 months prior to screening (defined as the onset of CSU determined by the investigator based on all available supporting documentation).
    - Diagnosis of CSU inadequately controlled by second generation H1-AH at the time of baseline (Day 1) defined as:
    -- The presence of itch and hives for ≥6 consecutive weeks prior to screening despite the use of second generation H1-AH during this time period.
    -- UAS7 score (range 0-42) ≥16, ISS7 score (range 0-21) ≥ 6 and HSS7 score (range 0-21) ≥ 6 during the 7 days prior to baseline (Day 1).
    - Documentation of hives within three months before baseline (either at screening and/or at baseline (Day 1); or documented in the participants` medical history).
    - Willing and able to complete an Urticaria Patient Daily Diary (UPDD) for the duration of the study and adhere to the study protocol.
    - Participants must not have had more than two missing UPDD entry (either morning or evening) in the 7 days prior to baseline (Day 1).
    - Se deberá obtener el consentimiento informado firmado antes de la participación en el estudio.
    - Participantes adultos de ambos sexos >=18 años de edad en el momento de la selección.
    - Duración de la UCE >=6 meses antes de la selección (definida como el inicio de la UCE determinado por el investigador según toda la documentación de apoyo disponible).
    - Diagnóstico de UCE inadecuadamente controlada con AH H1 de segunda generación en el momento de la basal (día 1) definido como:
    -- Presencia de picor y habones durante >=6 semanas consecutivas antes de la selección a pesar del uso de AH H1 de segunda generación durante este periodo de tiempo.
    -- Puntuación UAS7 (intervalo 0-42) >=16, puntuación ISS7 (intervalo 0-21) >=6 y puntuación HSS7 (intervalo 0-21) >=6 durante los 7 días anteriores a la basal (día 1).
    - Documentación de habones durante los tres meses anteriores a la basal (en la selección o en la basal [día 1]; o documentados en la historia clínica de los participantes).
    - Voluntad y capacidad para cumplimentar un diario del paciente de urticaria (DPU) durante el estudio y seguir el protocolo del estudio.
    - Los participantes no deben haber dejado sin rellenar más de dos entradas en el DPU (por la mañana o por la noche) en los 7 días anteriores a la basal (día 1).
    E.4Principal exclusion criteria
    - Use of other investigational drugs within 5 half-lives or within 30 days (for small molecules) prior to Screening or until the expected pharmacodynamic (PD) effect has returned to baseline (for biologics), whichever is longer; or longer if required by local regulations.
    - Previous use of remibrutinib or other BTK inhibitors.
    - History of hypersensitivity to any of the study treatments or its excipients or to drugs of similar chemical classes.
    - Participants having a clearly defined predominant or sole trigger of their chronic urticaria (chronic inducible urticaria) including urticaria factitia (symptomatic dermographism), cold-, heat-, solar-, pressure-, delayed pressure-, aquagenic-, cholinergic-, or contacturticaria.
    - Ongoing or past history of hypertension and/or SBP ≥140 or ≤90 and/or DBP ≥90 or ≤60 mmHg at screening.
    - Participants unable to tolerate 24-hour ambulatory blood pressure measurement prior to baseline.
    - Participants with an arm circumference greater than 50cm.
    - Other diseases with symptoms of urticaria or angioedema, including but not limited to urticarial vasculitis, urticaria pigmentosa, erythema multiforme, mastocytosis, hereditary angioedema, or drug-induced urticaria.
    - Any other skin disease associated with chronic itching that might influence, in the investigator’s opinion, the study evaluations and results, e.g., atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus or psoriasis.
    - Participants taking/requiring medications prohibited by the protocol
    - Known history or evidence of ongoing alcohol or drug abuse within the last 6 months before baseline (Day 1).
    - Participants working night shifts.
    - History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
    - Pregnant or nursing (lactating) women.
    - Evidence of clinically significant cardiovascular (such as but not limited to myocardial infarction, unstable ischemic heart disease, New York Heart Association (NYHA) Class III/IV left ventricular failure, arrhythmia and ongoing hypertension within 12 months prior to Visit 1), neurological, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, hematological disorders, gastrointestinal disease or immunodeficiency that, in the investigator's opinion, would compromise the safety of the participant, interfere with the interpretation of the study results or otherwise preclude participation or protocol adherence of the participant.
    Significant bleeding risk or coagulation disorders.
    - History of gastrointestinal bleeding.
    - Requirement for antiplatelet medication. The use of acetylsalicylic acid (up to 100mg/day) or clopidogrel (up to 75mg/day) is allowed after the completion of Week 4 visit.
    - Requirement for anticoagulant medication (for example, warfarin or Novel Oral Anti-Coagulants (NOAC)).
    - History or current hepatic disease including but not limited to acute or chronic hepatitis, cirrhosis or hepatic failure or Aspartate Aminotransferase (AST)/ Alanine Aminotransferase (ALT) levels of more than 1.5 x upper limit of normal (ULN) or International Normalized Ratio (INR) of more than 1.5 at screening.

    Other protocol-defined exclusion criteria may apply.
    - Uso de otros fármacos en investigación durante un periodo de 5 vidas medias o durante los 30 días anteriores a la selección (en caso de que se trate de moléculas pequeñas) o hasta que el efecto farmacodinámico (PD) previsto haya vuelto a los valores basales (en caso de que se trate de productos biológicos), aquel periodo que sea más largo; o durante un periodo más largo si la normativa local lo requiere.
    - Uso previo de remibrutinib u otros inhibidores de la BTK.
    - Antecedentes de hipersensibilidad a alguno de los tratamientos del estudio o sus excipientes o a fármacos de clases químicas similares.
    - Participantes con un factor desencadenante único o predominante, claramente definido, de su urticaria crónica (urticaria crónica inducible) incluida urticaria facticia (dermografismo sintomático), urticaria por frío, por calor, solar, por presión, por presión retardada, acuagénica, colinérgica o de contacto.
    - Antecedentes o historia actual de hipertensión y/o PAS >=140 o <=90 y/oO PAD >=90 o <=60 mmHg en la selección.
    - Participantes que no toleren la medición de la presión arterial ambulatoria (MAPA) en 24 horas mediante un dispositivo automático.
    - Participantes con una circunferencia del brazo superior a 50 cm.
    - Otras enfermedades con síntomas de urticaria o angioedema, que incluyen entre otras vasculitis urticarial, urticaria pigmentosa, eritema multiforme, mastocitosis, angioedema hereditario o urticaria inducida por fármacos.
    - Cualquier otra enfermedad cutánea asociada a picor crónico que pueda influir según el criterio del investigador en las evaluaciones y los resultados del estudio; p. ej., dermatitis atópica, penfigoide bulloso, dermatitis herpetiforme, prurito senil o psoriasis.
    - Participantes que tomen o necesiten medicación prohibida por el protocolo
    - Antecedentes o signos de abuso de alcohol o drogas en curso durante los 6 meses anteriores a la basal (día 1).
    - Participantes que trabajen en turnos de noche.
    - Antecedentes de tumor maligno de cualquier sistema orgánico (salvo carcinoma basocelular localizado de la piel o cáncer de cuello uterino in situ), tratado o no tratado, durante los últimos 5 años, independientemente de que existan o no pruebas de recurrencia local o metástasis.
    - Mujeres embarazadas o en periodo de lactancia.
    - Signos de trastornos cardiovasculares (como, entre otros, infarto de miocardio, enfermedad isquémica cardíaca inestable, insuficiencia ventricular izquierda de clase III/IV de la New York Heart Association (NYHA), arritmia e hipertensión en curso durante los 12 meses anteriores a la visita 1), y de trastornos neurológicos, psiquiátricos, pulmonares, renales, hepáticos, endocrinos, metabólicos y hematológicos, enfermedad gastrointestinal o inmunodeficiencia que sean de interés clínico y que, a juicio del investigador, pondrían en riesgo la seguridad del participante, interferirían en la interpretación de los resultados del estudio o impedirían de algún otro modo la participación o el cumplimiento del protocolo por parte del participante.
    Riesgo significativo de sangrado o trastornos de coagulación
    - Antecedentes de sangrado gastrointestinal.
    - Requisito de medicación antiplaquetaria. Se permite el uso de ácido acetilsalicílico (un máximo de 100 mg/día) o de clopidogrel (un máximo de 75 mg/día) después de completar la visita de la semana 4.
    - Requisito de medicación anticoagulante (Por ejemplo, warfarina o nuevos anticoagulantes orales (NACO)).
    - Antecedentes de enfermedad hepática o enfermedad hepática actual, incluidos entre otros, hepatitis aguda o crónica, cirrosis o insuficiencia hepática, niveles de aspartato aminotransferasa (AST)/alanina aminotransferasa (ALT) superiores a 1,5 x el límite superior de normalidad (LSN) o un índice internacional normalizado (INR) superior a 1,5 en la selección.

    Se podrían aplicar otros criterios de exclusión definidos en el protocolo.
    E.5 End points
    E.5.1Primary end point(s)
    The change in the ABPM-measured 24-hour weighted
    average SBP at Week 4 compared to baseline
    El cambio en la media ponderada de la PAS en 24 horas medida mediante MAPA en la semana 4 respecto a la basal.
    E.5.1.1Timepoint(s) of evaluation of this end point
    at Week 4
    En la semana 4
    E.5.2Secondary end point(s)
    1. The change in the ABPM-measured 24-hour weighted average SBP at Week 4 compared to baseline
    2. the change in the measured ABPM 24-hour weighted average DBP at Week 4 compared to baseline
    3. the change in the measured ABPM daytime and nighttime weighted average SBP at Week 4
    4. the change in the measured ABPM daytime and nighttime weighted average DBP at Week 4
    5. Occurrence of treatment emergent adverse events and serious adverse events (SAEs) during the study, evaluation of laboratory and vital signs data
    1. El cambio en la media ponderada de la PAS en 24 horas medida mediante MAPA en la semana 4 respecto a la basal.
    2. El cambio en la media ponderada de la PAD en 24 horas medida mediante MAPA en la semana 4 respecto a la basal.
    3. El cambio en la media ponderada de la PAS diurna y nocturna medida mediante MAPA en la semana 4.
    4. El cambio en la media ponderada de la PAD diurna y nocturna medida mediante MAPA en la semana 4.
    5. Aparición de acontecimientos adversos y acontecimientos adversos graves (AAG) con el tratamiento durante el estudio y evaluación de los datos de las pruebas analíticas y las constantes vitales.
    E.5.2.1Timepoint(s) of evaluation of this end point
    At Week 4
    Endpoint #5: End of study
    En la semana 4.
    Variable #5: fin del estudio
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Tolerability
    Tolerabilidad
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned5
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA23
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Canada
    Korea, Republic of
    Singapore
    United States
    France
    Spain
    Germany
    Slovakia
    Turkey
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months4
    E.8.9.1In the Member State concerned days17
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 123
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 13
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state15
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 69
    F.4.2.2In the whole clinical trial 136
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Participants who complete participation in the 12-week treatment period of this trial may be eligible to receive remibrutinib as part of an open-label extension study if they meet the eligibility criteria defined in the extension study protocol. The open-label extension will require endorsement in participating countries and sites as per local laws and regulations.
    Los participantes que completen su participación en el periodo de tratamiento de 12 semanas de este ensayo podrían ser elegibles para recibir remibrutinib en un estudio de extensión abierto si cumplen los criterios de elegibilidad definidos en el protocolo del estudio de extensión. En la extensión abierta, los países y los centros participantes deberán cumplir la legislación y la normativa locales.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2023-02-08
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2022-12-20
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 03 04:59:29 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA